Sugi Predict

Sugi Predict / Compounds / SCHEMBL1318307

SCHEMBL1318307

SCHEMBL1318307

CC1(C)OB(c2ccc3cn[nH]c3c2)OC1(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.45
▸ NOS1 P29475 3/20 0.45
▸ DYRK1A Q13627 2/20 0.45
▸ METAP2 P50579 2/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ PKM P14618 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ LPL P06858 4/20 0.44
▸ LIPG Q9Y5X9 4/20 0.44
▸ CYP3A4 P08684 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ IRAK4 Q9NWZ3 1/20 0.42
▸ FGFR1 P11362 6/20 0.41
▸ FGFR2 P21802 1/20 0.41
▸ FGFR3 P22607 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.39
▸ HSD17B10 Q99714 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29741038 1.00 MAPT (0.45) MAPTNOS1DYRK1AMETAP2KDM4E
SCHEMBL10475 0.88 NOS1 (0.45) MAPTNOS1DYRK1AMETAP2KDM4E
SCHEMBL4223024 0.81 MAPT (0.41) MAPTNOS1DYRK1AMETAP2KDM4E
SCHEMBL392405 0.80 PRMT5 (0.47) KDM4ELPLLIPGIRAK4ALDH1A1
SCHEMBL25234632 0.77 PRMT5 (0.47) LPLLIPGIRAK4ALDH1A1HSD17B10
SCHEMBL30399620 0.77 PRMT5 (0.47) LPLLIPGIRAK4ALDH1A1HSD17B10
SCHEMBL24595098 0.76 LIPG (0.45) LPLLIPGIRAK4
SCHEMBL29644319 0.75 LPL (0.62) LPLLIPGIRAK4HIF1A
SCHEMBL1293460 0.75 LPL (0.62) LPLLIPGIRAK4HIF1A
SCHEMBL20517030 0.75 TRPA1 (0.40) MAPTNOS1DYRK1AMETAP2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026102082-A1 ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE DEEP APPLE THERAPEUTICS, INC. (US) 2026-05-15 — — WO disclosed
US-20260132119-A1 Alkylphenyl Substituted Compounds, Compositions and Methods of Use DEEP APPLE THERAPEUTICS, INC. (US) 2026-05-14 — — US disclosed
CN-122010905-A Pyrazolyl derivatives as anticancer agents 诺华股份有限公司 2026-05-12 — — CN disclosed
US-20260124222-A1 ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
US-20260092053-A1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2026-04-02 — — US disclosed
US-20260078131-A1 PYRROLO-PYRIDAZINE INHIBITORS OF JAK2 AJAX THERAPEUTICS INC (US) 2026-03-19 — — US disclosed
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 — — US disclosed
US-12577248-B2 Substituted [1,2,4]triazolo[1,5-a]pyrazines as spleen tyrosine kinase inhibitors NANJING RUIJIE PHARMA CO., LTD. (CN) 2026-03-17 — — US disclosed
EP-4344702-B1 PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS NOVARTIS AG (CH) 2026-01-28 — — EP disclosed
EP-4681774-A2 KHK INHIBITORS Gilead Sciences, Inc. (US) 2026-01-21 — — EP disclosed
US-20110294776-A1 Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases BAYER HEALTHCARE AG (DE) 2011-12-01 — — US disclosed
US-20110275611-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC 2011-11-10 — — US disclosed
US-20110275611-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC 2011-11-10 — — US disclosed
US-20110275611-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC 2011-11-10 — — US disclosed
WO-2011112995-A1 IMIDAZOPYRIDINES SYK INHIBITORS GILEAD SCIENCES, INC. (US) 2011-09-15 — — WO disclosed
WO-2011112995-A1 IMIDAZOPYRIDINES SYK INHIBITORS GILEAD SCIENCES, INC. (US) 2011-09-15 — — WO disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 — — US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 — — US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 — — US disclosed
WO-2010059658-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078131-A1 PYRROLO-PYRIDAZINE INHIBITORS OF JAK2 JAK2, JAK1, JAK3 MAPT 4825/4885NOS1 387/4885DYRK1A 349/4885
US-20110275611-A1 CHEMICAL COMPOUNDS PDK1, PDK2, PDK3 MAPT 3565/4885NOS1 2419/4885DYRK1A 1041/4885
US-20110294776-A1 Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases IGF1R, FGFR1, IGFBP1 MAPT 3445/4885NOS1 1538/4885DYRK1A 639/4885
US-20260092053-A1 KHK INHIBITORS KHK, SLC5A2, HK1 MAPT 1585/4885NOS1 1762/4885DYRK1A 985/4885
US-20110201599-A1 CDK Modulators CDK3, CDK1, CDKL1 MAPT 2120/4885NOS1 3659/4885DYRK1A 546/4885
US-20260132119-A1 Alkylphenyl Substituted Compounds, Compositions and Methods of Use GIPR, MC2R, GRPR MAPT 4716/4885NOS1 4219/4885DYRK1A 1110/4885
US-20260078117-A1 COMPOUNDS AND METHODS OF USE NR3C2, ADRA1A, CNR1 MAPT 4259/4885NOS1 1666/4885DYRK1A 2974/4885
US-12577248-B2 Substituted [1,2,4]triazolo[1,5-a]pyrazines as spleen tyrosine kinase inhibitors SYK, BTK, TYRO3 MAPT 2032/4885NOS1 1189/4885DYRK1A 66/4885
US-20260124222-A1 ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL6B MAPT 4523/4885NOS1 683/4885DYRK1A 3362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.